OptiNose AS
1020 Stony Hill Road
Third Floor, Suite 300
Yardley
Pennsylvania
19067
United States
Tel: 267-364-3500
Fax: 267-395-2119
Website: http://www.optinose.com/
Email: info@optinose.com
132 articles about OptiNose AS
-
The FDA’s busy week ahead involves three decision dates for potential industry firsts and a highly anticipated advisory committee meeting for two CAR-T therapies.
-
Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights
3/7/2024
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter and year ended December 31, 2023, and provided recent operational highlights.
-
Optinose Announces Reporting Date for Fourth Quarter 2023 Financial ResultsConference Call and Webcast to be held March 7, 2024, at 8:00 a.m. Eastern Time
2/29/2024
Optinose, a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, announced the Company will report financial results for the fourth quarter 2023 and corporate updates, before market open on Thursday, March 7, 2024.
-
Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology: In Practice
1/18/2024
Optinose today announced peer-reviewed publication of results from both ReOpen1 and ReOpen2 in the Journal of Allergy and Clinical Immunology: In Practice1.
-
Optinose Announces 3-Month Extension of FDA Review Period for the Supplemental New Drug Application for XHANCE
12/6/2023
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that the U.S. Food and Drug Administration (FDA) has extended by three months the review period of its supplemental new drug application (sNDA) requesting approval of XHANCE as a treatment for chronic rhinosinusitis.
-
This week, the FDA could approve the first CRISPR-edited therapy in the U.S., while two other companies await decisions on topical drugs.
-
Optinose to Present at the 35th Annual Piper Sandler Healthcare Conference
11/22/2023
Optinose today announced that members of its management team will present a company overview and business update at the 35th Annual Piper Sandler Healthcare Conference on November 29, 2023, at 3:30 p.m. ET.
-
Optinose Reports Third Quarter 2023 Financial Results and Operational Updates
11/9/2023
Optinose, a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, reported financial results for the quarter ended September 30, 2023, and provided operational updates.
-
Optinose Announces Reporting Date for Third Quarter 2023 Financial Results
10/27/2023
Optinose, a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, announced the Company will report financial results for the third quarter 2023 and corporate updates, before market open on Thursday, November 9, 2023.
-
Optinose to Present at the 2023 Cantor Global Healthcare Conference
9/22/2023
Optinose today announced that members of its management team will present a company overview and business update at the 2023 Cantor Global Healthcare Conference on September 27, 2023 at 4:45 p.m. ET.
-
Optinose Reports Second Quarter 2023 Financial Results and Operational Updates
8/10/2023
Optinose, a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, reported financial results for the quarter ended June 30, 2023, and provided operational updates.
-
Optinose Announces Preliminary Second Quarter 2023 XHANCE Net Revenue of $19.5 Million
7/27/2023
Optinose today announced preliminary XHANCE ® (fluticasone propionate) net product revenue of $19.5 million for the three months ended June 30, 2023.
-
Optinose Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - June 16, 2023
6/16/2023
OptiNose, Inc. announced that the company has granted a non-qualified stock option award to purchase 100,000 shares of its common stock to a new employee as an inducement material for accepting employment with OptiNose.
-
Optinose to Present at the 2023 Jefferies Healthcare Conference
6/2/2023
Optinose announced that members of its management team will present a company overview and business update at the Jefferies Healthcare Conference on June 9, 2023 at 10:00 a.m. ET.
-
Optinose Reports First Quarter 2023 Financial Results and Operational Updates
5/11/2023
Optinose, a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, reported financial results for the quarter ended March 31, 2023, and provided operational updates.
-
Optinose Announces FDA Acceptance of Supplemental New Drug Application for XHANCE
5/4/2023
Optinose today announced the U.S. Food and Drug Administration (FDA) accepted for review its supplemental new drug application (sNDA) requesting approval of XHANCE as a treatment for chronic rhinosinusitis.
-
Optinose Announces Reporting Date for First Quarter 2023 Financial Results
5/1/2023
Optinose, a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, announced the Company will report financial results for the first quarter 2023 and corporate updates, before market open on Thursday, May 11, 2023.
-
Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 18, 2023
4/18/2023
OptiNose, Inc. announced that the company has granted non-qualified stock option awards to purchase an aggregate of 54,000 shares of its common stock to three new employees as an inducement material for accepting employment with OptiNose.
-
Optinose to Present at the Needham Virtual Healthcare Conference - April 12, 2023
4/12/2023
Optinose, a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, announced that members of its management team will present a company overview and business update at the Needham Virtual Healthcare Conference on April 17, 2023 at 3:45 p.m. ET.
-
Optinose Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Highlights
3/7/2023
Optinose, a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, reported financial results for the quarter and year ended December 31, 2022, and provided recent operational highlights.